Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

• Bernd Fischer, former CFO of Spiele Max AG and elumeo SE, CFO and member of the Executive Board with immediate effect
• With extensive experience in corporate finance and capital market expertise, Mr. Fischer will be responsible for Cantourage's Finance and Investor Relations divisions

Berlin, 11 January 2023 – Cantourage Group SE (FRA:HIGH), a European medical cannabis leader, has appointed Bernd Fischer as its new Chief Financial Officer (CFO) effective January 1, 2023. The experienced financial expert will be responsible for Financial Planning, Accounting, Reporting, and Investor Relations.

In his position as CFO, Bernd Fischer will also become a member of Cantourage's management and board of directors and will be responsible for the company's strategic development along with CEO Philip Schetter. Following the successful listing at the Frankfurt Stock Exchange in November 2022, the company continues to target strong organic growth, which could be strengthened through acquisitions in the future under certain circumstances.
Bernd Fischer brings more than 15 years of experience in Corporate Finance, Mergers & Acquisitions and capital markets, including at Berlin Brands Group, where he was responsible for Accounting, Treasury and Payments, and elumeo SE. There, he was responsible for the successful IPO in 2015 as Managing Director, member and spokesman of the Board of Directors. Prior to that, he played a key role in the restructuring of Spiele Max AG as CFO and Deputy Chairman of the Management Board from 2011 to 2013.

Dr. Michael Ruoff, Chairman of Cantourage's Supervisory Board, comments: "We are delighted to have gained Bernd Fischer, an experienced personality with strong communication skills, as Cantourage's CFO. With him joining, we are broadening the company's management team after the stock exchange listing in November and will be able to drive Cantourage's development even faster in a dynamically growing market."

Bernd Fischer, CFO of Cantourage, said, "The market for medical cannabis in Germany and Europe offers enormous growth potential. Cantourage, with its platform that brings cannabis from around the world to Europe, and its innovative solutions for cannabinoid-based therapies, has created optimal conditions to achieve extraordinary things in the coming years. I am very excited to become a part of the next phase of Cantourage's growth story and to help shape the company's future together with its world-class team."

--- END---

About Cantourage

Cantourage is a publicly listed, leading European medical cannabis company. The Berlin-based company with subsidiaries in the United Kingdom and Poland, was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol. The company was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under the stock ticker “HIGH”. For more information visit: https://www.cantourage.com/en/about.

This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company's financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.

In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as "Relevant Persons"). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.

Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.